Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 302, Issue 5, 2012, Pages

  Zoppi, Silvia ^a,d   Madrigal, José L M ^a,d   Pérez Nievas, Beatriz G ^a,d   Marín Jiménez, Ignacio ^c   Caso, Javier R ^a,d   Alou, Luis ^a   García Bueno, Borja ^a,d   Colón, Arturo ^c   Manzanares, Jorge ^b   Luisa Gomez Lus M ^a   Menchén, Luis ^c,e   Leza, Juan C ^a,d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE NEUROCIENCIAS   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

CCl28; Cyclooxygenase; Immunoglobulin A; Nitric oxide; Stress; Synthase; Tight junctions

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CYCLOOXYGENASE 2; EDETATE CHROMIUM CR 51; IMMUNOGLOBULIN A; INDUCIBLE NITRIC OXIDE SYNTHASE; RIMONABANT;

ACOUSTIC STRESS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIUM; BARRIER CONTRACEPTION; CELL MEMBRANE PERMEABILITY; COLON; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; GASTROINTESTINAL TRACT; IMMOBILIZATION; IMMUNOGLOBULIN PRODUCTION; INFLAMMATION; INTESTINE FUNCTION; INTESTINE MUCOSA; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; BACTERIAL TRANSLOCATION; CHROMIUM RADIOISOTOPES; COLON; CYCLOOXYGENASE 2; EDETIC ACID; IMMUNOGLOBULIN A; INTESTINAL MUCOSA; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; PERMEABILITY; RECEPTOR, CANNABINOID, CB1; RESTRAINT, PHYSICAL; STRESS, PSYCHOLOGICAL; ULTRASONICS;

EID: 84857345877     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00158.2011     Document Type: Article

References (54)

1. Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, Garratt RC. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. J Biol Chem 282: 18625-18633, 2007.
2. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 55: 1512-1520, 2006.
3. Banan A, Farhadi A, Fields JZ, Zhang LJ, Shaikh M, Keshavarzian A. The delta-isoform of protein kinase C causes inducible nitric-oxide synthase and nitric oxide up-regulation: key mechanism for oxidantinduced carbonylation, nitration, and disassembly of the microtubule cytoskeleton and hyperpermeability of barrier of intestinal epithelia. J Pharmacol Exp Ther 305: 482-494, 2003.
4. Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 75: 2959-2970, 2004.
5. Barreau F, Cartier C, Leveque M, Ferrier L, Moriez R, Laroute V, Rosztoczy A, Fioramonti J, Bueno L. Pathways involved in gut mucosal barrier dysfunction induced in adult rats by maternal deprivation: corticotrophin- releasing factor and nerve growth factor interplay. J Physiol 580: 347-356, 2007.
6. Bhatia V, Tandon RK. Stress and the gastrointestinal tract. J Gastroenterol Hepatol 20: 332-339, 2005.
7. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 108: 1566-1581, 1995.
8. Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation. Biochim Biophys Acta 1771: 952-960, 2007.
9. Caso JR, Leza JC, Menchen L. The effects of physical and psychological stress on the gastro-intestinal tract: lessons from animal models. Curr Mol Med 8: 299-312, 2008.
10. Collins SM. Stress and the Gastrointestinal Tract IV. Modulation of intestinal inflammation by stress: basic mechanisms and clinical relevance. Am J Physiol Gastrointest Liver Physiol 280: G315-G318, 2001.
11. Demaude J, Salvador-Cartier C, Fioramonti J, Ferrier L, Bueno L. Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: implications for delayed epithelial barrier dysfunction. Gut 55: 655-661, 2006.
12. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 34: 385-396, 2002.
13. Duncan M, Mouihate A, Mackie K, Keenan CM, Buckley NE, Davison JS, Patel KD, Pittman QJ, Sharkey KA. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide- treated rats. Am J Physiol Gastrointest Liver Physiol 295: G78-G87, 2008.
14. Esposito G, Izzo AA, Di Rosa M, Iuvone T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J Neurochem 78: 835-841, 2001.
15. Fioramonti J, Gebhart GF. In vivo and transgenic animal models used to study visceral hypersensitivity. Neurogastroenterol Motil 19: 20-28, 2007.
16. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 124: 3-20; quiz 21-22, 2009.
17. Han X, Fink MP, Yang R, Delude RL. Increased iNOS activity is essential for intestinal epithelial tight junction dysfunction in endotoxemic mice. Shock 21: 261-270, 2004.
18. Hieshima K, Kawasaki Y, Hanamoto H, Nakayama T, Nagakubo D, Kanamaru A, Yoshie O. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol 173: 3668-3675, 2004.
19. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 141: 1335-1345, 2004.
20. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161-202, 2002.
21. Ihenetu K, Molleman A, Parsons ME, Whelan CJ. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 458: 207-215, 2003.
22. Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 60: 117-125, 2009.
23. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 126: 21-38, 2010.
24. Jeon YJ, Yang KH, Pulaski JT, Kaminski NE. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor- kappa B/Rel activation. Mol Pharmacol 50: 334-341, 1996.
25. Kiank C, Holtfreter B, Starke A, Mundt A, Wilke C, Schutt C. Stress susceptibility predicts the severity of immune depression and the failure to combat bacterial infections in chronically stressed mice. Brain Behav Immun 20: 359-368, 2006.
26. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291: G364-G371, 2006.
27. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404, 1999.
28. Lepicier P, Bibeau-Poirier A, Lagneux C, Servant MJ, Lamontagne D. Signaling pathways involved in the cardioprotective effects of cannabinoids. J Pharm Sci 102: 155-166, 2006.
29. Li S, Wang C, Wang W, Dong H, Hou P, Tang Y. Chronic mild stress impairs cognition in mice: from brain homeostasis to behavior. Life Sci 82: 934-942, 2008.
30. Madara JL. Loosening tight junctions. Lessons from the intestine. J Clin Invest 83: 1089-1094, 1989.
31. Madara JL, Stafford J. Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83: 724-727, 1989.
32. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209, 2004.
33. Mazzon E, Sturniolo GC, Puzzolo D, Frisina N, Fries W. Effect of stress on the paracellular barrier in the rat ileum. Gut 51: 507-513, 2002.
34. O'Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337: 824-831, 2005.
35. Ogawa H, Iimura M, Eckmann L, Kagnoff MF. Regulated production of the chemokine CCL28 in human colon epithelium. Am J Physiol Gastrointest Liver Physiol 287: G1062-G1069, 2004.
36. Pare WP. Prior stress and susceptibility to stress ulcer. Physiol Behav 36: 1155-1159, 1986.
37. Ponferrada A, Caso JR, Alou L, Colon A, Sevillano D, Moro MA, Lizasoain I, Menchen P, Gomez-Lus ML, Lorenzo P, Cos E, Leza JC, Menchen L. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology 132: 1791-1803, 2007.
38. Rotllant D, Ons S, Carrasco J, Armario A. Evidence that metyrapone can act as a stressor: effect on pituitary-adrenal hormones, plasma glucose and brain c-fos induction. Eur J Neurosci 16: 693-700, 2002.
39. Sanger GJ. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 152: 663-670, 2007.
40. Santos J, Saunders PR, Hanssen NP, Yang PC, Yates D, Groot JA, Perdue MH. Corticotropin-releasing hormone mimics stress-induced colonic epithelial pathophysiology in the rat. Am J Physiol Gastrointest Liver Physiol 277: G391-G399, 1999.
41. Saunders PR, Kosecka U, McKay DM, Perdue MH. Acute stressors stimulate ion secretion and increase epithelial permeability in rat intestine. Am J Physiol Gastrointest Liver Physiol 267: G794-G799, 1994.
42. Sibaev A, Massa F, Yuce B, Marsicano G, Lehr HA, Lutz B, Goke B, Allescher HD, Storr M. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. J Mol Med (Berl) 84: 513-520, 2006.
43. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yuce B, Sibaev A, Massa F, Buckley NE, Lutz B, Goke B, Brand S, Patel KD, Sharkey KA. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) 86: 925-936, 2008.
44. Storr MA, Yuce B, Andrews CN, Sharkey KA. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 20: 857-868, 2008.
45. Sun Y, Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res 2007: 23513, 2007.
46. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809, 2009.
47. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169: 1901-1909, 2006.
48. Weymer A, Huott P, Liu W, McRoberts JA, Dharmsathaphorn K. Chloride secretory mechanism induced by prostaglandin E1 in a colonic epithelial cell line. J Clin Invest 76: 1828-1836, 1985.
49. Wilhelmsen I. The role of psychosocial factors in gastrointestinal disorders. Gut 47, Suppl 4: iv73-iv75, 2000.
50. Woof JM, Mestecky J. Mucosal immunoglobulins. Immunol Rev 206: 64-82, 2005.
51. Wright K, Rooney N, Feeney M, Tate J, Robertson D, Welham M, Ward S. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129: 437-453, 2005.
52. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153: 263-270, 2008.
53. Zheng K, Trivedi M, Siahaan TJ. Structure and function of the intercellular junctions: barrier of paracellular drug delivery. Curr Pharm Des 12: 2813-2824, 2006.
54. Zoppi S, Perez Nievas BG, Madrigal JL, Manzanares J, Leza JC, Garcia-Bueno B. Regulatory role of cannabinoid receptor 1 in stressinduced excitotoxicity and neuroinflammation. Neuropsychopharmacology 36: 805-818, 2011.